The biotech company, 1STBIO, is focused on discovering and developing innovative first-in-class therapeutic candidates with a high likelihood of clinical success. With a team of 24 experts in biochemistry, medicinal chemistry, pharmacology, and business development, the company is connected to a wide network of R&D professionals in academia, hospitals, industry, CROs, and investors in Korea, China, and the US. Their goal is to discover and develop effective molecular therapeutics for patients, with a deep pipeline of first-in-class investigational therapeutics for degenerative brain diseases, immuno-oncology, and rare diseases.